Tassos Gianakakos (MyoKardia)

'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

MyoKar­dia said its lead drug has de­liv­ered a clean sweep in a Phase III tri­al, val­i­dat­ing its ground­break­ing idea for bring­ing pre­ci­sion med­i­cine to car­diomy­opathies and paving the way for an NDA fil­ing ear­ly next year.

Con­sis­ten­cy was the theme trumped by the top team in a con­fer­ence call, where Marc Sem­i­gran, SVP of med­ical sci­ences, of­fered some more num­bers on the pri­ma­ry end­point and a slate of sec­ondary end­points be­yond the stel­lar p-val­ues in the re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.